Sanguine Corporation Supplies PHER-O2 to European Medical Research Group for Intravenous Development and Evaluation
PASADENA, Calif.--(BUSINESS WIRE)--Sanguine Corporation (OTC Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, supplies newly manufactured PHER-O2 to a European Pharmaceutical Company. The group is evaluating PHER-O2 for intravenous applications.